Review



cd44 pe cy7  (Cytek Biosciences)


Bioz Verified Symbol Cytek Biosciences is a verified supplier
Bioz Manufacturer Symbol Cytek Biosciences manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cytek Biosciences cd44 pe cy7
    a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ <t>CD44</t> + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.
    Cd44 Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd44 pe cy7/product/Cytek Biosciences
    Average 93 stars, based on 14 article reviews
    cd44 pe cy7 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza virus vaccine adjuvanted with bacterial cell membrane-derived adjuvants"

    Article Title: Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza virus vaccine adjuvanted with bacterial cell membrane-derived adjuvants

    Journal: bioRxiv

    doi: 10.1101/2025.02.26.640278

    a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.
    Figure Legend Snippet: a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.

    Techniques Used: Flow Cytometry, Incubation, Sequencing

    a. Body weight dynamics and survival after the heterologous challenge with 5 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1 reassortant with A/Puerto Rico/8/1934 vaccine backbone) and A/New Caledonia/20/1999 (H1N1) (n = 8). b. Viral titers in lungs and nasal turbinates on day 4 after the challenge (n = 4). c. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells) in mouse lungs and spleens 5 days after the challenge with 0.1 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. d. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.
    Figure Legend Snippet: a. Body weight dynamics and survival after the heterologous challenge with 5 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1 reassortant with A/Puerto Rico/8/1934 vaccine backbone) and A/New Caledonia/20/1999 (H1N1) (n = 8). b. Viral titers in lungs and nasal turbinates on day 4 after the challenge (n = 4). c. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells) in mouse lungs and spleens 5 days after the challenge with 0.1 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. d. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.

    Techniques Used: Flow Cytometry, Incubation, Sequencing



    Similar Products

    cd44-pe-cy7 im7 antibody  (Thermo Fisher)
    90
    Thermo Fisher cd44-pe-cy7 im7 antibody
    Cd44 Pe Cy7 Im7 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd44-pe-cy7 im7 antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    cd44-pe-cy7 im7 antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    pe-cy7-conjugated anti-cd44  (Thermo Fisher)
    90
    Thermo Fisher pe-cy7-conjugated anti-cd44
    Pe Cy7 Conjugated Anti Cd44, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe-cy7-conjugated anti-cd44/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    pe-cy7-conjugated anti-cd44 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    pe-cy7-conjugated anti-cd44 (im7)  (Thermo Fisher)
    90
    Thermo Fisher pe-cy7-conjugated anti-cd44 (im7)
    Pe Cy7 Conjugated Anti Cd44 (Im7), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe-cy7-conjugated anti-cd44 (im7)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    pe-cy7-conjugated anti-cd44 (im7) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    anti-cd44-pe-cy7 25–0441-82  (Thermo Fisher)
    90
    Thermo Fisher anti-cd44-pe-cy7 25–0441-82
    Anti Cd44 Pe Cy7 25–0441 82, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd44-pe-cy7 25–0441-82/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-cd44-pe-cy7 25–0441-82 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    anti-cd44-pe-cy7  (Thermo Fisher)
    90
    Thermo Fisher anti-cd44-pe-cy7
    Anti Cd44 Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd44-pe-cy7/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-cd44-pe-cy7 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    antibody anti-cd44-pe-cy7  (Thermo Fisher)
    90
    Thermo Fisher antibody anti-cd44-pe-cy7
    Antibody Anti Cd44 Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody anti-cd44-pe-cy7/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    antibody anti-cd44-pe-cy7 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cd44 im7 pe-cy7  (Thermo Fisher)
    90
    Thermo Fisher cd44 im7 pe-cy7
    Cd44 Im7 Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd44 im7 pe-cy7/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    cd44 im7 pe-cy7 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cd44 pe cy7  (Cytek Biosciences)
    93
    Cytek Biosciences cd44 pe cy7
    a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ <t>CD44</t> + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.
    Cd44 Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd44 pe cy7/product/Cytek Biosciences
    Average 93 stars, based on 1 article reviews
    cd44 pe cy7 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    apc-efluor780 pe-cy7-antibody cd44 im7  (Thermo Fisher)
    90
    Thermo Fisher apc-efluor780 pe-cy7-antibody cd44 im7
    a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ <t>CD44</t> + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.
    Apc Efluor780 Pe Cy7 Antibody Cd44 Im7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc-efluor780 pe-cy7-antibody cd44 im7/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    apc-efluor780 pe-cy7-antibody cd44 im7 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    pe-cy7-antibody to cd44  (Thermo Fisher)
    90
    Thermo Fisher pe-cy7-antibody to cd44
    a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ <t>CD44</t> + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.
    Pe Cy7 Antibody To Cd44, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe-cy7-antibody to cd44/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    pe-cy7-antibody to cd44 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.

    Journal: bioRxiv

    Article Title: Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza virus vaccine adjuvanted with bacterial cell membrane-derived adjuvants

    doi: 10.1101/2025.02.26.640278

    Figure Lengend Snippet: a. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes in mouse lungs and spleens 10 days after the booster immunization (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. b. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.

    Article Snippet: For the analysis of T- and B-cell populations in lungs, spleen, and NALTs, cells were stained with the antibody cocktail, including the following antibodies: CD38-AF488 (0.125 μl, BioLegend), PD-1-PE/Dazzle (0.5 μl, BioLegend), CD273-RB744 (0.25 μl, BD Biosciences), CD138-PE (0.25 μl, BioLegend), CD103-PE-Cy5.5 (0.5 μl, BioLegend), CD44-PE/Cy7 (0.25 μl, Tonbo Biosciences), GL7-APC (0.25 μl, BioLegend), CD69-AF700 (1 μl, BioLegend), CD62L-APC/Cy7 (0.125 μl, BioLegend), CD185-BV421 (0.5 μl, BioLegend), CD80-BV605 (1 μl, BioLegend), IgD-BV650 (0.25 μl, BioLegend), CD3-BV711 (0.5 μl, BioLegend), CD8-BV785 (0.25 μl, BioLegend), CD4-BUV496 (0.125 μl, BD Biosciences), IgM-BUV737 (1 μl, BD Biosciences), CD19-BUV805 (0.125 μl, BD Biosciences).

    Techniques: Flow Cytometry, Incubation, Sequencing

    a. Body weight dynamics and survival after the heterologous challenge with 5 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1 reassortant with A/Puerto Rico/8/1934 vaccine backbone) and A/New Caledonia/20/1999 (H1N1) (n = 8). b. Viral titers in lungs and nasal turbinates on day 4 after the challenge (n = 4). c. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells) in mouse lungs and spleens 5 days after the challenge with 0.1 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. d. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.

    Journal: bioRxiv

    Article Title: Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza virus vaccine adjuvanted with bacterial cell membrane-derived adjuvants

    doi: 10.1101/2025.02.26.640278

    Figure Lengend Snippet: a. Body weight dynamics and survival after the heterologous challenge with 5 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1 reassortant with A/Puerto Rico/8/1934 vaccine backbone) and A/New Caledonia/20/1999 (H1N1) (n = 8). b. Viral titers in lungs and nasal turbinates on day 4 after the challenge (n = 4). c. Representative flow cytometry plots showing the percentage of IL-2- and TNFα-producing CD4 + EM T-lymphocytes (gated on live CD3 + CD19 ‒ CD4 + CD62L ‒ CD44 + cells) in mouse lungs and spleens 5 days after the challenge with 0.1 × LD 50 of A/bald eagle/Florida/W22-134-OP/2022 (H5N1). Cells were incubated with overlapping peptides, covering the whole sequence of N1 NA-protein for 6h in the presence of Brefeldin A and co-stimulatory anti-CD28 antibodies. d. Percentage of different cytokine-producing cell populations within the total CD4 + EM T-cell subset after background subtraction. Average and SE values are shown. Statistical analyses were performed using one-way ANOVA with Tukey posthoc test. P-values for the groups with statistically significant differences are shown on the plots.

    Article Snippet: For the analysis of T- and B-cell populations in lungs, spleen, and NALTs, cells were stained with the antibody cocktail, including the following antibodies: CD38-AF488 (0.125 μl, BioLegend), PD-1-PE/Dazzle (0.5 μl, BioLegend), CD273-RB744 (0.25 μl, BD Biosciences), CD138-PE (0.25 μl, BioLegend), CD103-PE-Cy5.5 (0.5 μl, BioLegend), CD44-PE/Cy7 (0.25 μl, Tonbo Biosciences), GL7-APC (0.25 μl, BioLegend), CD69-AF700 (1 μl, BioLegend), CD62L-APC/Cy7 (0.125 μl, BioLegend), CD185-BV421 (0.5 μl, BioLegend), CD80-BV605 (1 μl, BioLegend), IgD-BV650 (0.25 μl, BioLegend), CD3-BV711 (0.5 μl, BioLegend), CD8-BV785 (0.25 μl, BioLegend), CD4-BUV496 (0.125 μl, BD Biosciences), IgM-BUV737 (1 μl, BD Biosciences), CD19-BUV805 (0.125 μl, BD Biosciences).

    Techniques: Flow Cytometry, Incubation, Sequencing